89bio appoints francis sarena as chief operating officer

San francisco, aug. 07, 2024 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of francis sarena as chief operating officer, effective august 5, 2024.
ETNB Ratings Summary
ETNB Quant Ranking